
Nikoletta Fotaki

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8055612/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Performance Evaluation of Montelukast Pediatric Formulations: Part l—Age-Related In Vitro Conditions. AAPS Journal, 2022, 24, 26.	4.4	1
2	Performance Evaluation of Montelukast Pediatric Formulations: Part II — a PBPK Modelling Approach. AAPS Journal, 2022, 24, 27.	4.4	2
3	Oral administration of buparvaquone nanostructured lipid carrier enables in vivo activity against Leishmania infantum. European Journal of Pharmaceutical Sciences, 2022, 169, 106097.	4.0	7
4	Understanding the Impact of Age-Related Changes in Pediatric GI Solubility by Multivariate Data Analysis. Pharmaceutics, 2022, 14, 356.	4.5	0
5	In vitro - in vivo relations for the parenteral liposomal formulation of Amphotericin B: A clinically relevant approach with PBPK modeling. European Journal of Pharmaceutics and Biopharmaceutics, 2021, 159, 177-187.	4.3	5
6	In vitro in vivo relations for the parenteral liposomal formulation of Amphotericin B: A biorelevant and clinically relevant approach. European Journal of Pharmaceutics and Biopharmaceutics, 2021, 159, 188-197.	4.3	5
7	Affinity of Lipophilic Drugs to Mixed Lipid Aggregates in Simulated Gastrointestinal Fluids. Journal of Pharmaceutical Sciences, 2021, 110, 186-197.	3.3	2
8	Predicting budesonide performance in healthy subjects and patients with Crohn's disease using biorelevant in vitro dissolution testing and PBPK modeling. European Journal of Pharmaceutical Sciences, 2021, 157, 105617.	4.0	8
9	Investigating the Impact of Crohn's Disease on the Bioaccessibility of a Lipid-Based Formulation with an In Vitro Dynamic Gastrointestinal Model. Molecular Pharmaceutics, 2021, 18, 1530-1543.	4.6	8
10	Current challenges and future perspectives in oral absorption research: An opinion of the UNGAP network. Advanced Drug Delivery Reviews, 2021, 171, 289-331.	13.7	84
11	Investigating the Critical Variables of Azithromycin Oral Absorption Using In Vitro Tests and PBPK Modeling. Journal of Pharmaceutical Sciences, 2021, 110, 3874-3888.	3.3	2
12	Highlights from the 2020 AAPS 360 Annual Meeting. Dissolution Technologies, 2021, 28, 36-40.	0.6	1
13	Evaluating pediatric and adult simulated fluids solubility: Abraham solvation parameters and multivariate analysis. Pharmaceutical Research, 2021, 38, 1889.	3.5	1
14	In vitro conditions for performance evaluation of products for intravascular administration: Developing appropriate test media using Amphotericin B as a model drug. European Journal of Pharmaceutical Sciences, 2020, 143, 105174.	4.0	3
15	On the Design of Food Effect Studies in Adults for Extrapolating Oral Drug Absorption Data to Infants: an Exploratory Study Highlighting the Importance of Infant Food. AAPS Journal, 2020, 22, 6.	4.4	11
16	Establishing virtual bioequivalence and clinically relevant specifications using in vitro biorelevant dissolution testing and physiologically-based population pharmacokinetic modeling. case example: Naproxen. European Journal of Pharmaceutical Sciences, 2020, 143, 105170.	4.0	58
17	Successful Extrapolation of Paracetamol Exposure from Adults to Infants After Oral Administration of a Pediatric Aqueous Suspension Is Highly Dependent on the Study Dosing Conditions. AAPS Journal, 2020, 22, 126.	4.4	9
18	Impact of Food and Drink Administration Vehicles on Paediatric Formulation Performance Part 2: Dissolution of Montelukast Sodium and Mesalazine Formulations. AAPS PharmSciTech, 2020, 21, 287.	3.3	9

#	Article	IF	CITATIONS
19	In Vivo Predictive Dissolution Testing of Montelukast Sodium Formulations Administered with Drinks and Soft Foods to Infants. AAPS PharmSciTech, 2020, 21, 282.	3.3	9
20	BCS-based biowaivers: Extension to paediatrics. European Journal of Pharmaceutical Sciences, 2020, 155, 105549.	4.0	5
21	Interpolymer Complexes of Eudragit® Copolymers as Novel Carriers for Colon-Specific Drug Delivery. Polymers, 2020, 12, 1459.	4.5	18
22	Biopharmaceutical implications of excipient variability on drug dissolution from immediate release products. European Journal of Pharmaceutics and Biopharmaceutics, 2020, 154, 195-209.	4.3	10
23	Factors Affecting Successful Extrapolation of Ibuprofen Exposure from Adults to Pediatric Populations After Oral Administration of a Pediatric Aqueous Suspension. AAPS Journal, 2020, 22, 146.	4.4	6
24	Gastrointestinal diseases and their impact on drug solubility: Crohn's disease. European Journal of Pharmaceutical Sciences, 2020, 152, 105459.	4.0	8
25	The use of PBPK/PD to establish clinically relevant dissolution specifications for zolpidem immediate release tablets. European Journal of Pharmaceutical Sciences, 2020, 155, 105534.	4.0	10
26	Co-administration of Paediatric Medicines with Food and Drinks in the Context of Their Physicochemical Properties—a Global Perspective on Practices and Recommendations. AAPS Journal, 2020, 22, 54.	4.4	12
27	Impact of Food and Drink Administration Vehicles on Paediatric Formulation Performance: Part 1—Effects on Solubility of Poorly Soluble Drugs. AAPS PharmSciTech, 2020, 21, 177.	3.3	12
28	Gastrointestinal diseases and their impact on drug solubility: Celiac disease. European Journal of Pharmaceutical Sciences, 2020, 152, 105460.	4.0	4
29	Gastrointestinal diseases and their impact on drug solubility: Ulcerative Colitis. European Journal of Pharmaceutical Sciences, 2020, 152, 105458.	4.0	5
30	Biopharmaceutical Understanding of Excipient Variability on Drug Apparent Solubility Based on Drug Physicochemical Properties: Case Study—Hypromellose (HPMC). AAPS Journal, 2020, 22, 49.	4.4	8
31	Development of an Aerosol Dose Collection Apparatus for In Vitro Dissolution Measurements of Orally Inhaled Drug Products. AAPS Journal, 2020, 22, 47.	4.4	19
32	Investigation of drug partition kinetics to fat in simulated fed state gastric conditions based on drug properties European Journal of Pharmaceutical Sciences, 2020, 146, 105263.	4.0	5
33	Biopharmaceutical Understanding of Excipient Variability on Drug Apparent Solubility Based on Drug Physicochemical Properties. Case Study: Superdisintegrants. AAPS Journal, 2020, 22, 46.	4.4	12
34	Surface dissolution UV imaging for characterization of superdisintegrants and their impact on drug dissolution. International Journal of Pharmaceutics, 2020, 577, 119080.	5.2	10
35	Impact of Magnesium Stearate Presence and Variability on Drug Apparent Solubility Based on Drug Physicochemical Properties. AAPS Journal, 2020, 22, 75.	4.4	13
36	A new medium-throughput screening design approach for the development of hydroxymethylnitrofurazone (NFOH) nanostructured lipid carrier for treating leishmaniasis. Colloids and Surfaces B: Biointerfaces, 2020, 193, 111097.	5.0	9

#	Article	IF	CITATIONS
37	Impact of gastrointestinal disease states on oral drug absorption – implications for formulation design – a PEARRL review. Journal of Pharmacy and Pharmacology, 2019, 71, 674-698.	2.4	53
38	Biopharmaceutical considerations in paediatrics with a view to the evaluation of orally administered drug products $\hat{a} \in $ a PEARRL review. Journal of Pharmacy and Pharmacology, 2019, 71, 603-642.	2.4	29
39	Effects of medicines used to treat gastrointestinal diseases on the pharmacokinetics of coadministered drugs: a PEARRL Review. Journal of Pharmacy and Pharmacology, 2019, 71, 643-673.	2.4	11
40	In Vitro–In Vivo Correlations Based on In Vitro Dissolution of Parent Drug Diltiazem and Pharmacokinetics of its Metabolite. Pharmaceutics, 2019, 11, 344.	4.5	12
41	Co-delivery of buparvaquone and polymyxin B in a nanostructured lipid carrier for leishmaniasis treatment. Journal of Global Antimicrobial Resistance, 2019, 18, 279-283.	2.2	14
42	Biorelevant release testing of biodegradable microspheres intended for intra-articular administration. European Journal of Pharmaceutics and Biopharmaceutics, 2019, 139, 115-122.	4.3	7
43	Highly Water-Soluble Orotic Acid Nanocrystals Produced by High-Energy Milling. Journal of Pharmaceutical Sciences, 2019, 108, 1848-1856.	3.3	14
44	Potential prediction of formulation performance in paediatric patients using biopharmaceutical tools and simulation of clinically relevant administration scenarios of nifedipine and lorazepam. British Journal of Clinical Pharmacology, 2019, 85, 1728-1739.	2.4	14
45	Application of the relationship between pharmacokinetics and pharmacodynamics in drug development and therapeutic equivalence: a PEARRL review. Journal of Pharmacy and Pharmacology, 2019, 71, 699-723.	2.4	16
46	Surface Dissolution UV Imaging for Investigation of Dissolution of Poorly Soluble Drugs and Their Amorphous Formulation. AAPS PharmSciTech, 2019, 20, 113.	3.3	20
47	Preliminary pharmacokinetic study of the anticancer 6BIO in mice using an UHPLC-MS/MS approach. Journal of Pharmaceutical and Biomedical Analysis, 2019, 164, 317-325.	2.8	4
48	Strategic drug analysis in fed-state gastric biorelevant media based on drug physicochemical properties. European Journal of Pharmaceutics and Biopharmaceutics, 2018, 127, 326-341.	4.3	10
49	Investigation and simulation of dissolution with concurrent degradation under healthy and hypoalbuminaemic simulated parenteral conditions- case example Amphotericin B. European Journal of Pharmaceutics and Biopharmaceutics, 2018, 127, 423-431.	4.3	3
50	In Vitro and In Silico ADME Prediction. , 2018, , 301-330.		5
51	In Vivo Predictive Dissolution and Simulation Workshop Report: Facilitating the Development of Oral Drug Formulation and the Prediction of Oral Bioperformance. AAPS Journal, 2018, 20, 100.	4.4	7
52	Impact of presence of excipients in drug analysis in fed-state gastric biorelevant media. European Journal of Pharmaceutics and Biopharmaceutics, 2018, 131, 178-188.	4.3	1
53	Dissolution Highlights from the 2017 AAPS Annual Meeting in San Diego. Dissolution Technologies, 2018, 25, 78-83.	0.6	0
54	Influence of Sex and Food on the Bioavailability and the R-to-S Conversion of Ketoprofen Stereoisomers in Humans. European Journal of Drug Metabolism and Pharmacokinetics, 2017, 42, 167-169.	1.6	0

#	Article	lF	CITATIONS
55	Understanding and predicting the impact of critical dissolution variables for nifedipine immediate release capsules by multivariate data analysis. International Journal of Pharmaceutics, 2017, 518, 41-49.	5.2	10
56	Considerations for the development of in vitro dissolution tests to reduce or replace preclinical oral absorption studies. European Journal of Pharmaceutical Sciences, 2017, 99, 193-201.	4.0	22
57	Recommended strategies for the oral administration of paediatric medicines with food and drinks in the context of their biopharmaceutical properties: a review. Journal of Pharmacy and Pharmacology, 2017, 69, 384-397.	2.4	22
58	Biopharmaceutical aspects and implications of excipient variability in drug product performance. European Journal of Pharmaceutics and Biopharmaceutics, 2017, 111, 1-15.	4.3	75
59	Dissolution Highlights from the 2016 AAPS Annual Meeting in Denver. Dissolution Technologies, 2017, 24, 68-72.	0.6	Ο
60	Fed-state gastric media and drug analysis techniques: Current status and points to consider. European Journal of Pharmaceutics and Biopharmaceutics, 2016, 107, 234-248.	4.3	21
61	Towards the development of a paediatric biopharmaceutics classification system: Results of a survey of experts. International Journal of Pharmaceutics, 2016, 511, 1151-1157.	5.2	17
62	An in vitro–in vivo correlation study for nifedipine immediate release capsules administered with water, alcoholic and non-alcoholic beverages: Impact of in vitro dissolution media and hydrodynamics. International Journal of Pharmaceutics, 2016, 499, 330-342.	5.2	12
63	Assessment of Age-Related Changes in Pediatric Gastrointestinal Solubility. Pharmaceutical Research, 2016, 33, 52-71.	3.5	48
64	Small-Scale Assays for Studying Dissolution of Pharmaceutical Cocrystals for Oral Administration. AAPS PharmSciTech, 2016, 17, 245-251.	3.3	16
65	Dissolution Highlights from the 2015 AAPS Annual Meeting in Orlando. Dissolution Technologies, 2016, 23, 42-47.	0.6	2
66	Sex-related in vitro/in vivo and PK/PD correlations after oral single dose furosemide administration. Journal of Pharmaceutical Technology & Drug Research, 2016, 5, 2.	1.0	3
67	Meeting Report: AAPS–NIFDC Joint Workshop on Dissolution Testing, Biowaiver, and Bioequivalence. Dissolution Technologies, 2016, 23, 46-55.	0.6	0
68	<scp>BU</scp> 08073 a buprenorphine analogue with partial agonist activity at μâ€receptors <i>in vitro</i> but longâ€lasting opioid antagonist activity <i>in vivo</i> in mice. British Journal of Pharmacology, 2015, 172, 668-680.	5.4	32
69	Enhanced paracellular transport of insulin can be achieved via transient induction of myosin light chain phosphorylation. Journal of Controlled Release, 2015, 210, 189-197.	9.9	59
70	Parameterization of small intestinal water volume using PBPK modeling. European Journal of Pharmaceutical Sciences, 2015, 67, 55-64.	4.0	6
71	Dissolution Highlights from the 2014 AAPS Annual Meeting in San Diego. Dissolution Technologies, 2015, 22, 56-58.	0.6	0
72	Paediatric oral biopharmaceutics: Key considerations and current challenges. Advanced Drug Delivery Reviews, 2014, 73, 102-126.	13.7	104

#	Article	IF	CITATIONS
73	Sex- and smoke-related differences in gastrointestinal transit of cyclosporin A microemulsion capsules. European Journal of Pharmaceutical Sciences, 2014, 63, 140-146.	4.0	7
74	Dissolution Highlights from the 2013 AAPS Annual Meeting in San Antonio. Dissolution Technologies, 2014, 21, 44-46.	0.6	0
75	Pharmaceutical characterisation and evaluation of cocrystals: Importance of in vitro dissolution conditions and type of coformer. International Journal of Pharmaceutics, 2013, 453, 380-388.	5.2	42
76	Mechanistic Understanding of the Effect of PPIs and Acidic Carbonated Beverages on the Oral Absorption of Itraconazole Based on Absorption Modeling with Appropriate in Vitro Data. Molecular Pharmaceutics, 2013, 10, 4016-4023.	4.6	18
77	Survey Results for In Vitro-In Vivo Correlations (IVIVC): Critical Variables for Success. Dissolution Technologies, 2013, 20, 48-50.	0.6	11
78	Rationale for Selection of Dissolution Media: Three Case Studies. Dissolution Technologies, 2013, 20, 6-13.	0.6	16
79	Dissolution Highlights from the 2012 AAPS Annual Meeting in Chicago. Dissolution Technologies, 2013, 20, 57-59.	0.6	Ο
80	Dissolution Highlights from the 2011 AAPS Annual Meeting in Washington, D. C Dissolution Technologies, 2012, 19, 69-70.	0.6	0
81	Flow-Through Cell Apparatus (USP Apparatus 4): Operation and Features. Dissolution Technologies, 2011, 18, 46-49.	0.6	47
82	2010 Pharmaceutical Sciences World Congress Provides Dissolution Programming with an International Flavor. Dissolution Technologies, 2011, 18, 38-42.	0.6	0
83	Dissolution media simulating the intralumenal composition of the small intestine: physiological issues and practical aspectsâ€. Journal of Pharmacy and Pharmacology, 2010, 56, 453-462.	2.4	206
84	Intestinal permeability and excretion into bile control the arrival of amlodipine into the systemic circulation after oral administration. Journal of Pharmacy and Pharmacology, 2010, 58, 827-836.	2.4	16
85	Biorelevant Dissolution Methods and Their Applications in In Vitro- In Vivo Correlations for Oral Formulations~!2009-09-14~!2009-11-02~!2010-04-29~!. Open Drug Delivery Journal, 2010, 4, 2-13.	2.0	89
86	A comparative study of different release apparatus in generating in vitro–in vivo correlations for extended release formulations. European Journal of Pharmaceutics and Biopharmaceutics, 2009, 73, 115-120.	4.3	59
87	Pros and cons of methods used for the prediction of oral drug absorption. Expert Review of Clinical Pharmacology, 2009, 2, 195-208.	3.1	11
88	Biorelevant Dissolution: Methodology and Application in Drug Development. Dissolution Technologies, 2009, 16, 6-12.	0.6	42
89	Predictive models for oral drug absorption: from in silico methods to integrated dynamical models. Expert Opinion on Drug Metabolism and Toxicology, 2007, 3, 491-505.	3.3	39
90	Predictive models for oral drug absorption: from in silico methods to integrated dynamical models. Expert Opinion on Drug Metabolism and Toxicology, 2007, 3, 491-505.	3.3	11

#	Article	IF	CITATIONS
91	In vitro versus canine data for predicting input profiles of isosorbide-5-mononitrate from oral extended release products on a confidence interval basis. European Journal of Pharmaceutical Sciences, 2005, 24, 115-122.	4.0	53
92	Canine versus in vitro data for predicting input profiles of l-sulpiride after oral administration. European Journal of Pharmaceutical Sciences, 2005, 26, 324-333.	4.0	48
93	The Flow Through Cell Methodology in the Evaluation of Intralumenal Drug Release Characteristics. Dissolution Technologies, 2005, 12, 17-21.	0.6	27
94	Using in silico process simulation tools in pharmacy education: Considerations for pivoting to online learning. Pharmacy Education, 0, , 124-135.	0.6	0